Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-07-34 | Oral Session 7: Thyroid Cancer Basic | ETA2022

CDK4 phosphorylation status and rational use of CDK4/6 inhibitors in advanced thyroid cancers

Pita Jaime M , Coulonval Katia , Costante Giuseppe , Myriam Decaussin , Emmanuelle Leteurtre , Cavaco Branca , A Copland John , Durante Cosimo , Maenhaut Carine , Dumont Jacques , Roger Pierre , Raspe Eric

Introduction and objectives: The cyclin-dependent kinases CDK4 and CDK6 are key regulators of the cell cycle entry, by phosphorylating the onco-suppressor retinoblastoma protein (pRb). CDK4/6 inhibitors (CDK4i) are already established as standard first-line treatment against advanced Estrogen Receptor-positive breast tumors, and have emerged as novel drugs to treat various pRb-proficient chemotherapy-resistant cancers. Presence of activating T172-phosphorylation of CDK4 in bre...

ea0041gp235 | Thyroid Cancer (1) | ECE2016

Thyroid nodules: a highly specific molecular and cytological combined predictor of malignancy

Lasolle Helene , Riche Benjamin , Decaussin Myriam , Dantony Emmanuelle , Cornu Catherine , Lifante Jean-Christophe , Capraru Oana-Maria , Rousset Bernard , Borson-Chazot Francoise , Roy Pascal

Thyroid nodules are very common and benign in most cases. Thus, malignancy detection avoiding overtreatment is a challenge. Nodule evaluation mainly supports on US and fine needle aspiration cytology (FNAC). The Bethesda classification (BC) for reporting thyroid cytopathology is now currently used for the interpretation of results but it does not enable classifying 30% of samples.The objective was to identify, by transcriptome analysis, a molecular signa...